PTC Therapeutics, Inc. (PTCT) Analysts See $-0.87 EPS

October 13, 2017 - By test

 PTC Therapeutics, Inc. (PTCT) Analysts See $ 0.87 EPS
Investors sentiment decreased to 0.92 in 2017 Q2. Its down 0.24, from 1.16 in 2017Q1. It fall, as 17 investors sold PTC Therapeutics, Inc. shares while 34 reduced holdings. 17 funds opened positions while 30 raised stakes. 31.07 million shares or 6.35% more from 29.21 million shares in 2017Q1 were reported.
Bogle Inv Mngmt Ltd Partnership De holds 0.81% in PTC Therapeutics, Inc. (NASDAQ:PTCT) or 609,921 shares. Moreover, Meeder Asset Management has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 49 shares. Barclays Public Ltd Liability Company accumulated 90,961 shares. The Massachusetts-based Wellington Management Group Ltd Liability Partnership has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Goldman Sachs Group Incorporated owns 227,477 shares. 20,682 were accumulated by Gp Inc Inc. Savings Bank Of Montreal Can invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Virginia Retirement Sys Et Al holds 18,400 shares or 0% of its portfolio. Invesco Ltd has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Venbio Select Advisor Limited Company holds 0.28% in PTC Therapeutics, Inc. (NASDAQ:PTCT) or 120,000 shares. California State Teachers Retirement Sys holds 59,041 shares. Cornerstone holds 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT) or 50 shares. Frontier Capital Mngmt Communication Ltd Liability Company holds 0.18% or 1.31M shares in its portfolio. Consonance Capital Mgmt Lp, New York-based fund reported 3.95 million shares. Swiss State Bank, Switzerland-based fund reported 56,565 shares.

Since May 23, 2017, it had 1 buy, and 0 sales for $337,230 activity.

Wall Street await PTC Therapeutics, Inc. (NASDAQ:PTCT) to release earnings on November, 1. Analysts forecast EPS of $-0.87, up exactly $0.16 or 15.53 % from 2014’s $-1.03 EPS. After posting $-0.44 EPS for the previous quarter, PTC Therapeutics, Inc.’s analysts now forecast 97.73 % negative EPS growth. The stock increased 0.17% or $0.03 during the last trading session, reaching $17.86. About 528,373 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since October 13, 2016 and is uptrending. It has outperformed by 87.81% the S&P500.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 11 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 5 Hold. Therefore 36% are positive. PTC Therapeutics had 30 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) rating on Wednesday, August 9. RBC Capital Markets has “Hold” rating and $1500 target. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Wednesday, February 24 report. The firm earned “Sector Perform” rating on Friday, November 11 by RBC Capital Markets. The company was initiated on Wednesday, January 20 by Credit Suisse. Credit Suisse downgraded the stock to “Neutral” rating in Tuesday, July 26 report. Cowen & Co maintained the shares of PTCT in report on Friday, June 30 with “Hold” rating. Oppenheimer maintained the stock with “Outperform” rating in Thursday, February 25 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Buy” rating by Citigroup on Friday, November 11. Jefferies downgraded it to “Underperform” rating and $18 target in Wednesday, November 25 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Outperform” rating by Oppenheimer on Friday, October 16.

PTC Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $739.21 million. The Firm is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid biology. It currently has negative earnings. The Company’s product pipeline includes Ataluren (Translarna), PTC596 and RG7916.

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Streetinsider.com which released: “PTC Therapeutics (PTCT) Announces Spinal Muscular Atrophy Program Advanced …” on October 12, 2017, also Prnewswire.com with their article: “Long-Term PTC Investors: Johnson Fistel Initiates Investigation of PTC …” published on September 27, 2017, Marketwatch.com published: “PTC Therapeutics gains after FDA panel votes against drug approval” on September 28, 2017. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Benzinga.com and their article: “US Approval Of PTC Therapeutics’ Translarna ‘Remains Unlikely'” published on September 29, 2017 as well as Fool.com‘s news article titled: “Why PTC Therapeutics, Inc. Dropped Today” with publication date: October 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.